Understanding Generic Versus Brand Name Medications in Immune Conditions

Why this matters

Being dispensed a medication that looks different from usual, has a different name, or comes in different packaging can feel unsettling. Understanding what has and hasn’t changed makes it easier to take medication with confidence, and to know when a question to the pharmacist or GP is genuinely warranted.

What generic actually means

When a branded medication's patent expires, other manufacturers are permitted to produce the same drug. These are generics. They must contain the same active ingredient, at the same dose, and meet the same regulatory standards for safety and quality. What can differ is the inactive ingredients: fillers, coatings, and dyes. For most people, this makes no practical difference.

The price is usually lower, which is why pharmacies often dispense generics automatically. This is standard practice, not a reduction in care quality.

Where the distinction matters more

For most standard medications used in immune conditions, including methotrexate, hydroxychloroquine, and azathioprine, generic substitution is straightforward. Two areas tend to come up most often and are worth understanding clearly.

Narrow therapeutic index drugs. Some medications, such as certain immunosuppressants, where the effective dose and the toxic dose are very close together, require stable blood levels. Switching between formulations, even of the same drug, can sometimes affect absorption enough to matter. If on one of these medications and a switch is being considered, it’s worth discussing with the prescribing clinician first.

Biosimilars. Biological medications, such as adalimumab or rituximab, cannot be copied in the same way as chemical drugs because they’re complex proteins produced in living cells. Biosimilars aren’t identical to the original but are shown to be highly similar in terms of safety and effectiveness. Switching to a biosimilar is generally considered safe and is common practice in the NHS, but it’s reasonable to ask for an explanation if a switch is proposed. Newly diagnosed patients are likely to be started on biosimilar medications from the outset, such as in rheumatoid arthritis.

What you could do

If a dispensed medication looks different from usual, check the active ingredient on the label rather than the brand name. If the active ingredient and dose are the same, it’s likely a generic substitution.

• If uncertain whether a substitution is appropriate for a specific medication, ask the pharmacist before leaving
• If on a narrow therapeutic index drug and a switch has been made without discussion, raise it with the GP or specialist
• If a biosimilar switch is proposed, asking the clinician or specialist nurse to explain what is changing and why is a reasonable way to feel informed

This article is for general information purposes only and doesn’t constitute legal, financial or benefits advice. For advice specific to your situation, please speak to a qualified professional or contact an organisation such as Citizens Advice, who may be able to assist you further.

References:

A review of the differences and similarities between generic drugs and their originator counterparts' (2013) https://doi.org/10.1186/2050-6511-14-1

'Biosimilars and generics' (2024) https://indepth.nice.org.uk/biosimilars-and-generics/index.html

‘Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis’ (2008) https://doi.org/10.1001/jama.2008.758